Moleculin Biotech financials
$0.5264−7.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$7.6M | -$7.9M | -$7.5M | -$5.9M | -$5.7M | -$5.9M | -$6.6M | -$7.1M | -$6.2M | -$6.7M | -$8.9M | -$5.9M |
| Net income | -$8.0M | -$14.6M | $15.4M | -$25.4M | -$17.8M | -$5.9M | -$6.6M | -$7.0M | -$4.3M | -$5.0M | -$10.3M | -$5.6M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.40 | $-3.54 | — | $-17.00 | $-28.68 | $-15.80 | $-9.32 | $-47.25 | $-42.50 | $-50.50 | $-127.14 | $-70.50 |
| EBITDA | -$7.6M | -$7.9M | -$7.5M | -$5.9M | -$5.7M | -$5.9M | -$6.6M | -$7.1M | -$6.2M | -$6.6M | -$8.9M | -$5.9M |
| Operating cash flow | -$6.7M | -$6.1M | -$5.4M | -$7.2M | -$5.6M | -$4.6M | -$5.1M | -$6.1M | -$5.9M | -$6.7M | -$4.9M | -$7.6M |
| Free cash flow | -$6.7M | -$6.1M | -$5.4M | -$7.2M | -$5.6M | -$4.6M | -$5.1M | -$6.1M | -$6.0M | -$6.7M | -$5.0M | -$7.6M |
| Diluted shares | 5.7M | 4.1M | — | 1.5M | 0.6M | 0.4M | 0.2M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.3M | $10.3M | $8.9M | $6.7M | $7.6M | $7.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $21.1M | $23.4M | $22.1M | $20.4M | $21.6M | $21.0M |
| Total liabilities | $9.5M | $8.2M | $7.1M | $47.3M | $28.8M | $21.0M |
| Shareholders' equity | $11.6M | $15.2M | $15.0M | -$26.9M | -$7.2M | $42.0K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology